250 related articles for article (PubMed ID: 31860754)
1. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
[TBL] [Abstract][Full Text] [Related]
2. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
3. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
Kimura K; Tsuzuki T; Kato M; Saito AM; Sassa N; Ishida R; Hirabayashi H; Yoshino Y; Hattori R; Gotoh M
Prostate; 2014 May; 74(6):680-7. PubMed ID: 24481730
[TBL] [Abstract][Full Text] [Related]
5. Prognostic parameter for high risk prostate cancer patients at initial presentation.
Kato M; Kimura K; Hirakawa A; Kobayashi Y; Ishida R; Kamihira O; Majima T; Funahashi Y; Sassa N; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2018 Jan; 78(1):11-16. PubMed ID: 29094384
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
[TBL] [Abstract][Full Text] [Related]
7. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
[TBL] [Abstract][Full Text] [Related]
8. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
[TBL] [Abstract][Full Text] [Related]
9. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
11. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy.
Wang B; Fu Y; Chen M; Peng S; Marra G; Zhuang J; Zhang S; Guo H; Qiu X
Urol Oncol; 2024 Mar; 42(3):67.e9-67.e15. PubMed ID: 38233262
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
Hajili T; Ohlmann CH; Linxweiler J; Niklas C; Janssen M; Siemer S; Stoeckle M; Saar M
BJU Int; 2019 Jan; 123(1):58-64. PubMed ID: 29772100
[TBL] [Abstract][Full Text] [Related]
13. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
15. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
Zhu S; Zhao JG; Chen JR; Liu ZH; Sun GX; Wang ZP; Ni YC; Dai JD; Shen PF; Zeng H
Asian J Androl; 2020; 22(5):519-525. PubMed ID: 31710002
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
[TBL] [Abstract][Full Text] [Related]
18. Associations Between Intraductal Prostate Cancer and Metastases Following Radical Prostatectomy in Men With Prostate Cancer in the Veterans Affairs Database.
Nelson TJ; Kumar A; Nalawade V; Nonato T; Shabaik A; Roma A; Rose BS; McKay RR
Clin Genitourin Cancer; 2023 Aug; 21(4):452-458. PubMed ID: 37095044
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
20. The Influence of the Intraductal Carcinoma of the Prostate on the Short-Term Oncological Outcomes.
Kalemci S; Kizilay F; Simsir A; Emre Ergun K; Kose T
Arch Esp Urol; 2022 Jun; 75(5):405-409. PubMed ID: 35983810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]